<p>泰尔茂（Terumo (TRUMF)）已发布其第二季度财报。以下是泰尔茂向投资者提供的信息概述。</p>
<h3>认识您的 ETF AI 分析师</h3>
<ul>
<li>了解 TipRanks 的 <em>ETF</em> AI 分析师如何帮助您做出更明智的投资决策</li>
<li>探索 TipRanks 用户喜爱的 ETF，并查看 <strong><em>ETF</em> AI 分析师</strong> 对您关注的 ETF 所揭示的见解。</li>
</ul>
<p>泰尔茂公司是一家在医疗技术领域的知名企业，专注于医疗设备和器械的开发与制造，特别关注心脏和血管解决方案、医疗护理以及血液和细胞技术。</p>
<p>在截至 2025 年 9 月 30 日的六个月最新财报中，泰尔茂公司报告了稳健的财务表现，收入和利润显著增长，得益于全球扩张和战略业务发展。</p>
<p>公司实现收入 5349 亿日元，同比增长 5.2%，海外市场，尤其是美洲和欧洲，贡献显著。心脏和血管公司引领增长，收入增长 5.2%，而血液和细胞技术公司则因血浆创新的进展实现了 9.2% 的增长。调整后的营业利润增长 10%，达到 1144 亿日元，凸显了公司的强大运营效率。</p>
<p>泰尔茂的财务状况依然强劲，总资产增加至 18948 亿日元，得益于在制造设施和业务收购上的战略投资。公司的经营活动现金流保持稳定，同时在扩大生产能力和收购新业务资产方面进行了重大投资。</p>
<p>展望未来，泰尔茂公司对其增长前景持乐观态度，上调了全年收入和调整后营业利润的指引。公司继续专注于扩大全球业务和提升产品供应，以满足医疗技术领域日益增长的需求。</p>

泰尔茂(ADR)

4543

<p>泰尔茂（Terumo Corporation，股票代码：TRUMF）公布了截至 2025 年 9 月 30 日的六个月第二季度强劲财报，收入为 5349 亿日元，同比增长 5.2%。增长主要得益于海外市场，尤其是美洲和欧洲。心脏与血管公司和血液与细胞技术公司贡献显著，收入分别增长了 5.2% 和 9.2%。调整后的营业利润增长了 10%，达到 1144 亿日元。泰尔茂对未来持乐观态度，上调了全年收入和利润指引，专注于全球扩张和医疗技术领域的产品提升</p>

<p>Terumo ( (TRUMF) ) has released its Q2 earnings. Here is a breakdown of the information Terumo presented to its investors.</p>
<div class="lb-trans"><p>泰尔茂（Terumo (TRUMF)）已发布其第二季度财报。以下是泰尔茂向投资者提供的信息概述。</p>
</div><h3>Meet Your ETF AI Analyst</h3>
<div class="lb-trans"><h3>认识您的 ETF AI 分析师</h3>
</div><ul>
<li>Discover how TipRanks' <em>ETF</em> AI Analyst can help you make smarter investment decisions</li>
<li>Explore ETFs TipRanks' users love and see what insights the <strong><em>ETF</em> AI Analyst</strong> reveals about the ones you follow.</li>
</ul>
<div class="lb-trans"><ul>
<li>了解 TipRanks 的 <em>ETF</em> AI 分析师如何帮助您做出更明智的投资决策</li>
<li>探索 TipRanks 用户喜爱的 ETF，并查看 <strong><em>ETF</em> AI 分析师</strong> 对您关注的 ETF 所揭示的见解。</li>
</ul>
</div><p>Terumo Corporation, a prominent player in the medical technology sector, specializes in the development and manufacturing of medical devices and equipment, with a strong focus on cardiac and vascular solutions, medical care, and blood and cell technologies.</p>
<div class="lb-trans"><p>泰尔茂公司是一家在医疗技术领域的知名企业，专注于医疗设备和器械的开发与制造，特别关注心脏和血管解决方案、医疗护理以及血液和细胞技术。</p>
</div><p>In its latest earnings report for the six months ending September 30, 2025, Terumo Corporation reported a solid financial performance, marked by a notable increase in revenue and profits, driven by global expansion and strategic business developments.</p>
<div class="lb-trans"><p>在截至 2025 年 9 月 30 日的六个月最新财报中，泰尔茂公司报告了稳健的财务表现，收入和利润显著增长，得益于全球扩张和战略业务发展。</p>
</div><p>The company achieved a revenue of ¥534.9 billion, reflecting a 5.2% increase year-on-year, with significant contributions from its overseas markets, particularly in the Americas and Europe. The Cardiac and Vascular Company led the growth with a 5.2% increase in revenue, while the Blood and Cell Technologies Company saw a 9.2% rise, bolstered by advancements in plasma innovation. Adjusted operating profit rose by 10% to ¥114.4 billion, underlining the company’s robust operational efficiency.</p>
<div class="lb-trans"><p>公司实现收入 5349 亿日元，同比增长 5.2%，海外市场，尤其是美洲和欧洲，贡献显著。心脏和血管公司引领增长，收入增长 5.2%，而血液和细胞技术公司则因血浆创新的进展实现了 9.2% 的增长。调整后的营业利润增长 10%，达到 1144 亿日元，凸显了公司的强大运营效率。</p>
</div><p>Terumo’s financial position remains strong, with total assets increasing to ¥1,894.8 billion, supported by strategic investments in manufacturing facilities and business acquisitions. The company’s cash flow from operating activities remained stable, while significant investments were made in expanding production capabilities and acquiring new business assets.</p>
<div class="lb-trans"><p>泰尔茂的财务状况依然强劲，总资产增加至 18948 亿日元，得益于在制造设施和业务收购上的战略投资。公司的经营活动现金流保持稳定，同时在扩大生产能力和收购新业务资产方面进行了重大投资。</p>
</div><p>Looking ahead, Terumo Corporation remains optimistic about its growth prospects, with an upward revision of its full-year revenue and adjusted operating profit guidance. The company continues to focus on expanding its global footprint and enhancing its product offerings to meet the growing demand in the medical technology sector.</p>
<div class="lb-trans"><p>展望未来，泰尔茂公司对其增长前景持乐观态度，上调了全年收入和调整后营业利润的指引。公司继续专注于扩大全球业务和提升产品供应，以满足医疗技术领域日益增长的需求。</p>
</div>

泰尔茂公司报告显示财务增长强劲